Skip to Content

New Drug Approvals Archive - June 2013

June 2013

Rixubis (coagulation factor IX (recombinant)) Injection

Date of Approval: June 26, 2013
Company: Baxter International Inc.
Treatment for: Hemophilia B

Rixubis (coagulation factor IX, recombinant) is an antihemophilic factor indicated for the control and prevention of bleeding episodes in adults with hemophilia B.

Read more: Rixubis (coagulation factor IX (recombinant)) FDA Approval History

Brisdelle (paroxetine mesylate) Capsules - formerly LDMP

Date of Approval: June 28, 2013
Company: Noven Pharmaceuticals, Inc.
Treatment for: Hot Flashes Associated with Menopause

Brisdelle (paroxetine mesylate) is a low-dose selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.

Read more: Brisdelle (paroxetine mesylate) FDA Approval History

New Drug Approvals Archive